Targeting Death Receptors in Bladder, Prostate and Renal Cancer
Authors:
- 1 February 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (2) , 432-438
Abstract
We describe key components of normal and aberrant death receptor pathways, the association of these abnormalities with tumorigenesis in bladder, prostate and renal cancer, and their potential application in novel therapeutic strategies targeted toward patients with cancer. A MEDLINE literature search of the key words death receptors, TRAIL (tumor necrosis factor related apoptosis inducing ligand), FAS, bladder, prostate, renal and cancer was done to obtain information for review. A brief overview of the TRAIL and FAS death receptor pathways, and their relationship to apoptosis is described. Mechanisms that lead to nonfunction of these pathways and how they may contribute to tumorigenesis are linked. Current efforts to target death receptor pathways as a therapeutic strategy are highlighted. Activation of tumor cell expressing death receptors by cytotoxic immune cells is the main mechanism by which the immune system eliminates malignant cells. Death receptor triggering induces a caspase cascade, leading to tumor cell apoptosis. Receptor gene mutation or hypermethylation, decoy receptor or splice variant over expression, and downstream inhibitor interference are examples of the ways that normal pathway functioning is lost in cancers of the bladder and prostate. Targeting death receptors directly through synthetic ligand administration and blocking downstream inhibitor molecules with siRNA or antisense oligonucleotides represent novel therapeutic strategies under development. Research into the death receptor pathways has demonstrated the key role that pathway aberrations have in the initiation and progression of malignancies of the bladder, prostate and kidney. This new understanding has resulted in exciting approaches to restore the functionality of these pathways as a novel therapeutic strategy.Keywords
This publication has 50 references indexed in Scilit:
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathwayOncogene, 2004
- In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancerCancer Gene Therapy, 2004
- Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate CancerCancer Research, 2004
- Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanismsThe Prostate, 2004
- Decreased Fas expression in advanced-stage bladder cancer is not related to p53 statusUrology, 2004
- Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancerThe Prostate, 2004
- Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expressionCancer Gene Therapy, 2003
- Human Urinary Bladder Transitional Cell Carcinomas Acquire the Functional Fas Ligand during Tumor ProgressionThe American Journal of Pathology, 2003
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999